胸腺切除术后恶性肿瘤与自身免疫疾病发生率:一项探索性研究
该研究回顾2008至2020年接受胸腺切除术的226例成人患者,中位随访6.0年,术后新发恶性肿瘤发生率为0.87例/100人年,与美国NCI SEER普通人群的0.81例/100人年相当;新发自身免疫疾病发生率为1.3例/100人年,高于大型人群研究报告的0.7例/100人年。
要点
- 胸腺切除术后新发恶性肿瘤发生率与普通人群相近。
- 术后新发自身免疫疾病发生率高于大型人群研究,与既往研究一致。
- 术后5年内累积恶性肿瘤发生率为4.6%,NCI数据为4%。
核心结论
- 在美国,胸腺切除术后新发恶性肿瘤的发生率与普通人群相似,但新发自身免疫疾病的发生率更高,与既往研究相符。
研究设计与样本
- 回顾性研究,纳入2008至2020年接受胸腺切除术的成人患者226例,中位年龄55岁(IQR 39-67),女性129例(57%),非吸烟者132例(58%),中位随访6.0年。
主要发现
- 术后观察到13例(6%)新发恶性肿瘤,发生率为0.87例/100人年,与NCI的0.81例/100人年相当。
- 术后5年内新发癌症发生率为0.92例/100人年,5年累积4.6%,NCI数据为4%。
- 观察到19例(8%)新发自身免疫疾病诊断,发生率为1.3例/100人年,高于大型人群研究的0.7例/100人年(全年龄段)。
关键数值与推荐
- 随访中134例随访超过5年,44例随访超过10年。
临床怎么用
- 胸腺切除术后需关注自身免疫疾病的新发风险,术后随访中应对自身免疫疾病保持警惕。
- 术后恶性肿瘤风险与普通人群相近,可按常规人群筛查策略管理。
局限性
- 为单中心回顾性探索性研究,样本量226例,随访时间有限(中位6.0年)。
- 自身免疫疾病发生率与既往发表结果比较,非同期对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Thymectomy reportedly increases the risk of cancer, autoimmune disease, and death. Studies are few and data limited. We sought to determine the incidence of postoperative malignancy and autoimmune disease in patients who underwent thymectomy. METHODS: We conducted a retrospective review of adult patients undergoing thymectomy between 2008 and 2020. Postoperative cancers and autoimmune disease were diagnosed after thymectomy. Incidence rates were calculated using patient-years and compared to the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) programme incidence of cancer for the US general population. Autoimmune disease rates were compared to previously published results. RESULTS: There were 226 patients with a median age of 55 years (interquartile range [IQR] = 39-67), mostly female (129, 57%) and non-smokers (132, 58%). At baseline, 117 (52%) had autoimmune disease, including 102 (45%) with myasthenia gravis. Eighty-four (37%) thymomas were identified. Median follow-up was 6.0 years (134 with >5-year follow-up and 44 with >10-year follow-up). We observed 13 (6%) new malignancies for an incidence of 0.87 cases/100 person-years (0.87%) and comparable to the NCI rate of 0.81 cases/100 person-years (0.81%). Incident cancers developed within the first 5 years after surgery at 0.92 cases/100 person-years (0.92%) or 4.6% cumulatively over 5 years, compared to NCI data at 4%. There were 19 (8%) new autoimmune diagnoses with an incidence rate of 1.3 cases/100 person-years (1.3%) and is higher than large population studies (0.7 cases/100 person-years for all ages). CONCLUSIONS: Development of new cancers following thymectomy in the United States is similar to the general population. But we identified a higher incidence of autoimmune disease, matching prior studies.
引用
- Hanson CE, White PT, Bograd AJ, et al. The Incidence of Malignancy and Autoimmune Disorders After Thymectomy: An Exploratory Study. Eur J Cardiothorac Surg. 2026. PMID: 41494982. doi:10.1093/ejcts/ezag018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。